Micronomicin sulfate (Gentamicin C2b sulfate) is an aminoglycoside antibiotic with antimicrobial activity that inhibits neuraminidase N1 of influenza A virus.

Escherichia coli St.M. 589:0.75 μg/ml (MIC), R5/W677:0.03 μg/ml (MIC), F 14-BK:0.03 μg/ml (MIC), Baker 2:0.3 μg/ml (MIC), Staphylococcus aureus FDA 209 P:0.01 μg/ml (MIC)

Micronomicin sulfate exhibited significant antibacterial activity with a MIC of 0.01 μg/ml against Staphylococcus aureus FDA 209 P and other strains, and a MIC of 0.75 μg/ml, 0.3 μg/ml, 0.03 μg/ml and 0.03 μg/ml against Escherichia coli St.M. 589, Baker 2, F 14-BK and R5/W677, respectively.In addition, it was found to be effective against Pseudomonas aeruginosa and Klebsiella pneumoniae strains with a MIC range of 0.03-17.5 μg/ml.[1]

Micronomicin sulfate has shown strong activity against a wide range of bacterial infections in mice, with an acute LD50 (lethal dose) of 93 mg/kg administered intravenously.[1]
In subacute toxicity studies, intravenous injections, 4-100 mg/kg Micronomicin sulfate, for 30 consecutive days were used in the test. At a dose of 100 mg/kg, 10 of the Wistar rats (out of a total of 30) died, exhibiting renal dysfunction and ataxia. Renal tissue lesions occurred mainly at doses of 25 mg/kg and above. [3]

H2O: 30.00 mg/mL, Sonication is recommended.